Pfizer to Close R&D Facility, Lay Off 120

Source: Financial Times

Dec 03, 2015

Pfizer plans to close a research and development facility in Cambridge, England, cutting up to 120 jobs.

The proposed closure of the research unit, known as Neusentis, is part of a broader decision to reduce early-stage R&D investment in pain therapies. Going forward, Pfizer will focus R&D efforts on neurodegenerative disease and neuropsychiatric disorders.

The cut comes on the heels of Pfizer’s $160 billion agreement last week to merge with Irish-registered Allergan.

Read the Financial Times article.

Make sure you didn't miss anything: view our monthly news recap


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments